StockData
10x Genomics, Inc. logo

10x Genomics, Inc. (TXG) stock

TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30111% above fair value
$56.30+1.31 (+2.38%)

Close on Nov 17, 2026Market cap $7.34BP/E –Yield –

10x Genomics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

10x Genomics's operating income for the twelve months ending Sep 30, 2026 was -$72.20M. For fiscal 2025 it was -$60.99M. The highest annual figure on record is -$18.38M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$60.99M–
FY2024Dec 31, 2024-$194.56M–
FY2023Dec 31, 2023-$265.33M–
FY2022Dec 31, 2022-$167.94M–
FY2021Dec 31, 2021-$52.25M–
FY2020Dec 31, 2020-$534.14M–
FY2019Dec 31, 2019-$30.57M–
FY2018Dec 31, 2018-$110.76M–
FY2017Dec 31, 2017-$18.38M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$16.06M–
Q2 FY2026Jun 30, 2026-$19.56M-164.9%
Q1 FY2026Mar 31, 2026-$17.05M–
Q4 FY2025Dec 31, 2025-$19.54M–
Q3 FY2025Sep 30, 2025-$32.24M–
Q2 FY2025Jun 30, 2025$30.13M–
Q1 FY2025Mar 31, 2025-$39.33M–
Q4 FY2024Dec 31, 2024-$49.84M–
Q3 FY2024Sep 30, 2024-$41.49M–
Q2 FY2024Jun 30, 2024-$41.74M–
Q1 FY2024Mar 31, 2024-$61.50M–
Q4 FY2023Dec 31, 2023-$55.19M–
Q3 FY2023Sep 30, 2023-$94.80M–
Q2 FY2023Jun 30, 2023-$63.36M–
Q1 FY2023Mar 31, 2023-$51.99M–
Q4 FY2022Dec 31, 2022-$23.10M–
Q3 FY2022Sep 30, 2022-$40.00M–
Q2 FY2022Jun 30, 2022-$63.12M–
Q1 FY2022Mar 31, 2022-$41.74M–
Q4 FY2021Dec 31, 2021-$15.83M–
Q3 FY2021Sep 30, 2021-$15.88M–
Q2 FY2021Jun 30, 2021-$10.33M–
Q1 FY2021Mar 31, 2021-$10.22M–
Q4 FY2020Dec 31, 2020-$409.58M–
Q3 FY2020Sep 30, 2020-$65.26M–
Q2 FY2020Jun 30, 2020-$39.42M–
Q1 FY2020Mar 31, 2020-$19.88M–
Q4 FY2019Dec 31, 2019-$8.08M–
Q3 FY2019Sep 30, 2019-$9.10M–
Q2 FY2019Jun 30, 2019-$10.36M–
Q1 FY2019Mar 31, 2019-$3.04M–
Q4 FY2018Dec 31, 2018-$74.97M–
Q3 FY2018Sep 30, 2018-$14.93M–

More 10x Genomics figures

See a number that looks wrong?